Kelun-Biotech is one of the pioneers and leading developers of ADCs with over ten years experience in ADC development. According to Frost & Sullivan, Kelun-Biotech is one of the first biopharmaceutical companies in China, and one of the few globally, to establish an integrated ADC development platform that supports our system development throughout the ADC's life cycle. Our ADC platform, OptiDC™ is supported by three pillars of capability: deep understanding of biological targets and diseases, tested and validated ADC design and development expertise, and a toolbox of ADC core components. Through over a decade of development, Kelun-Biotech has developed a toolbox of core ADC components that are able to engineer customized ADCs optimized against different biological targets to address medical needs in a broad range of indications. Kelun-Biotech has honed its expertise in ADC process development, manufacturing and quality control, which it believes is crucial in bringing the ADCs from bench to bedside.
Notably, the platform has been tested and validated on more than thousands of patients through clinical trials. By leveraging our experience and data from drug discovery, translational medicine, process development and clinical studies over years of implementing our ADC design strategies, we deploy a multi-pronged strategy to advance our ADC platform. For oncology diseases, we are developing ADCs as a replacement for chemo-based cancer therapies, by (i) developing ADCs targeting novel targets with monoclonal, biparatopic and bispecific antibodies; (ii) expanding cytotoxic agents beyond common TOPO1 and tubulin inhibitors; and (iii) optimizing our conjugation technologies to enable precise control of the positioning and number of conjugated payloads including dual payloads. We are also developing ADCs to replace non-chemo-based cancer therapies by developing ADC derivatives with innovative compound structure and diversified payloads other than cytotoxins such as radionuclide drug conjugates (RDCs), immunostimulatory ADCs (iADCs) and degrader-antibody conjugates (DACs), etc. Beyond oncology diseases, we are developing ADCs with non-cytotoxic payloads for other disease indications such as autoimmune disease.